Valuation: Rezolute, Inc.

Market Cap 513M 449M 412M 384M 728M 48.83B 739M 4.92B 1.92B 24B 1.93B 1.88B 82.8B P/E 2026 *
-7.01x
P/E 2027 * -7.55x
Enterprise Value 513M 449M 412M 384M 728M 48.83B 739M 4.92B 1.92B 24B 1.93B 1.88B 82.8B EV / Sales 2026 *
-
EV / Sales 2027 * 223x
Free-Float
89.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Rezolute, Inc.

1 day-0.81%
1 week-2.58%
Current month-5.58%
1 month+8.87%
3 months+57.37%
6 months+126.79%
Current year+108.05%
1 week 4.84
Extreme 4.84
5.42
1 month 3.7
Extreme 3.705
5.42
Current year 1.87
Extreme 1.87
5.42
1 year 1.07
Extreme 1.07
11.46
3 years 0.72
Extreme 0.72
11.46
5 years 0.72
Extreme 0.72
13.08
10 years 0.72
Extreme 0.72
100
Manager TitleAgeSince
Chief Executive Officer 58 2013-01-29
Director of Finance/CFO 52 2024-01-22
Chief Operating Officer - -
Director TitleAgeSince
Chairman 58 2022-05-03
Director/Board Member 55 2019-11-19
Chairman 68 2019-02-09
Date Insider Type Main position Quantity % Market Cap.
03-29Buy

Chief Financial Officer

10,000 0.0115%
03-01Tax

Chief Executive Officer

27,618 0.0317%
03-01Tax

Chief Financial Officer

11,438 0.0131%
Change 5-day change 1-year change 3-year change Capi.($)
-0.81%-2.58%+1.87%+142.47% 513M
+0.68%+5.92%+77.86%+139.22% 59.1B
+2.32%+5.03%+75.26%+91.40% 55.19B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+43.36%-4.67% 19.69B
-0.29%+9.78%+43.90%-28.41% 17.56B
0.00%+20.78%+186.15%+361.42% 16.22B
+6.72%+19.38%+37.85% - 14.84B
+3.50%+1.97%+21.02%+191.95% 14.04B
Average +2.50%+7.47%+49.00%+146.85% 24.6B
Weighted average by Cap. +2.46%+6.46%+58.21%+136.99%

Financials

2026 *2027 *
Net sales - 2.3M 2.01M 1.85M 1.73M 3.27M 219M 3.32M 22.1M 8.64M 108M 8.65M 8.46M 372M
Net income -72.7M -63.57M -58.42M -54.45M -103M -6.92B -105M -697M -273M -3.4B -273M -267M -11.74B -75.12M -65.69M -60.36M -56.26M -107M -7.15B -108M -721M -282M -3.51B -282M -276M -12.13B
Net Debt - -
Logo Rezolute, Inc.
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Employees
68
Date Price Change Volume
26-07-02 US$4.910 -0.81% 2,794,829
26-07-01 US$4.950 -4.81% 2,428,130
26-06-30 US$5.200 +1.96% 3,368,014
26-06-29 US$5.100 +1.19% 1,753,923
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.910USD
Average target price
7.667USD
Spread / Average Target
+56.14%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RZLT Stock